Cenix BioScience Takes on Second RNAi-Based Target Validation Project for CellCentric
News Jul 02, 2008
Cenix BioScience GmbH has announced that it has initiated a second target validation project under the framework research agreement signed previously with UK-based CellCentric Ltd, a biotechnology company developing therapeutics against a series of novel epigenetic targets.
The new project follows the success of the parties’ initial pilot together, wherein candidate drug targets chosen by CellCentric for their high therapeutic anti-cancer potential, were subjected by Cenix to RNAi-based phenotypic characterization using multi-parametric microscopy assays in a diverse panel of human cell lines.
Cenix will now apply the same combination of high throughput RNAi with own proprietary high content assays using the Definiens® Cellenger™ image analysis platform, to generate a detailed characterization of loss-of-function phenotypes for several more oncology target candidates across a new collection of human cell lines.
“The relationship with Cenix has been highly productive and we are pleased to be expanding the relationship to cover further novel epigenetic targets. We have been impressed both with the quality of the work conducted and the detailed reporting of results.” noted Will West, CEO of CellCentric.
“We at Cenix feel very gratified that the first dataset we delivered for the pilot study has already proven useful in driving forward the CellCentric oncology program,” said Dr. Christophe Echeverri, CEO/CSO of Cenix. “We therefore very much look forward to continuing this exciting and productive relationship through this second project”.
No other details were released.
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Genetic Diversity Helps Protect Against DiseaseNews
Why do populations have genetic diversity when 'Survival of the Fittest' suggests that only one gene pool should thrive? It's a question that is hard to answer experimentally. A new study looking at evolutionary change in real time in tiny fungal parasites may provide a solution.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE